Anaphylaxis and hypotension after administration of peginesatide

New England Journal of Medicine

Volumn 370, Issue 21, 2014, Pages 2055-2056

  Bennett, Charles L ^a   Jacob, Sony ^b   Hymes, Jeffrey ^c   Usvyat, Len A ^c   Maddux, Franklin W ^c  

^a University of South Carolina   (United States)

^b WJB Dorn VA Medical Center   (United States)

^c FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINESATIDE;

ADVERSE OUTCOME; ANAPHYLAXIS; ANEMIA; CARDIOPULMONARY INSUFFICIENCY; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG LABELING; DRUG MANUFACTURE; DRUG RECALL; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; HYPOTENSION; LETTER; PRIORITY JOURNAL;

ANAPHYLAXIS; ANEMIA; HEMATINICS; HUMANS; HYPOTENSION; PEPTIDES; RENAL DIALYSIS;

EID: 84901049498     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1400883     Document Type: Letter

References (5)

1. Bennett CL, Spiegel DM, Macdougall IC, et al. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012;38:783-96.
2. Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19.
3. Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320-32.
4. Food and Drug Administration. Revised package insert for Omontys (peginesatide). December 4, 2012 (http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/202799s001lbl.pdf).
5. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 2010;26:473-82.